TY - JOUR
T1 - Non-GVHD ocular complications after hematopoietic cell transplantation
T2 - expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
AU - Inamoto, Yoshihiro
AU - Petriček, Igor
AU - Burns, Linda
AU - Chhabra, Saurabh
AU - DeFilipp, Zack
AU - Hematti, Peiman
AU - Rovó, Alicia
AU - Schears, Raquel
AU - Shah, Ami
AU - Agrawal, Vaibhav
AU - Al-Khinji, Aisha
AU - Ahmed, Ibrahim
AU - Ali, Asim
AU - Aljurf, Mahmoud
AU - Alkhateeb, Hassan
AU - Beitinjaneh, Amer
AU - Bhatt, Neel
AU - Buchbinder, Dave
AU - Byrne, Michael
AU - Callander, Natalie
AU - Fahnehjelm, Kristina
AU - Farhadfar, Nosha
AU - Gale, Robert Peter
AU - Ganguly, Siddhartha
AU - Hildebrandt, Gerhard C.
AU - Horn, Erich
AU - Jakubowski, Ann
AU - Kamble, Rammurti T.
AU - Law, Jason
AU - Lee, Catherine
AU - Nathan, Sunita
AU - Penack, Olaf
AU - Pingali, Ravi
AU - Prasad, Pinki
AU - Pulanic, Drazen
AU - Rotz, Seth
AU - Shreenivas, Aditya
AU - Steinberg, Amir
AU - Tabbara, Khalid
AU - Tichelli, André
AU - Wirk, Baldeep
AU - Yared, Jean
AU - Basak, Grzegorz W.
AU - Battiwalla, Minoo
AU - Duarte, Rafael
AU - Savani, Bipin N.
AU - Flowers, Mary E.D.
AU - Shaw, Bronwen E.
AU - Valdés-Sanz, Nuria
N1 - Funding Information:
Acknowledgements The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biother-apeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members
Publisher Copyright:
© 2019, Springer Nature Limited.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.
AB - Non-graft-vs.-host disease (non-GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT), but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplant physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment, and ocular toxicities associated with medications. We have summarized incidence, risk factors, screening, prevention and treatment of individual complicastions and generated evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical symptoms, signs and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplant physicians and ophthalmologists should be knowledgeable of non-GVHD ocular complications and provide comprehensive collaborative team care.
UR - http://www.scopus.com/inward/record.url?scp=85058153231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058153231&partnerID=8YFLogxK
U2 - 10.1038/s41409-018-0339-6
DO - 10.1038/s41409-018-0339-6
M3 - Review article
C2 - 30531955
AN - SCOPUS:85058153231
SN - 0268-3369
VL - 54
SP - 648
EP - 661
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 5
ER -